Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05972616 · ClinicalTrials.gov registry record
Natural Matrix Protein™ (NMP™) in Interbody Lumbar Fusion
A clinical trial of Degenerative Disc Disease, sponsored by Induce Biologics USA.
- Completed
- Registry status
- 53
- Enrollment target
- 1
- Study location
NCT05972616: Completed study of Degenerative Disc Disease, sponsored by Induce Biologics USA.
NCT05972616 is a study of Degenerative Disc Disease that has completed, run by Induce Biologics USA. The registered enrollment target is 53 participants, below the 167-participant average among 42 other Degenerative Disc Disease trials with a reported enrollment target (68% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05972616, a study of Degenerative Disc Disease, has completed, sponsored by Induce Biologics USA.
- COMPLETED
- Registry status
- 53 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of this study is to evaluate the performance of Induce Biologics NMP™ when used to promote interbody fusion for degenerative disease of the lumbar spine.
Primary Outcome
CT scans will be graded from 0 (no boney ingrowth) to 3 (complete bridging) and A (no evidence of supplemental fixation failure) or B (evidence of supplemental fixation failure). Fusion will be defined as a CT grade of 3A with less than 3 degrees of motion at the index level on flexion and extension x-rays.
Conditions Studied
Interventions
- BIOLOGICAL Natural Matrix Protein (NMP)
Study Locations (1)
Louisiana
- Spine Institute of Louisiana - Shreveport
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2023-08-01 |
| Est. Completion | 2024-02-21 |
What the finished NCT05972616 record still lists
NCT05972616 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 53 participants, a relatively small participant target, below the 167-participant average among 42 other Degenerative Disc Disease trials with a reported enrollment target (68% lower).
The record links to 1 condition, with Degenerative Disc Disease appearing as the primary indexed condition, and to 1 intervention - of which Natural Matrix Protein (NMP) is the first listed.
NCT05972616 reports a single indexed study location in Louisiana.
Frequently Asked Questions
What is clinical trial NCT05972616 about?
NCT05972616 is a clinical study titled "Natural Matrix Protein™ (NMP™) in Interbody Lumbar Fusion". The objective of this study is to evaluate the performance of Induce Biologics NMP™ when used to promote interbody fusion for degenerative disease of the lumbar spine.
What is the current status of trial NCT05972616?
This trial is currently completed. The enrollment target is 53 participants. The study started on 2023-08-01. Estimated completion is 2024-02-21.
What conditions does trial NCT05972616 study?
This clinical trial studies the following conditions: Degenerative Disc Disease.
What interventions are being tested in trial NCT05972616?
The interventions under investigation include: Natural Matrix Protein (NMP) (BIOLOGICAL).
Who is sponsoring clinical trial NCT05972616?
This trial is sponsored by Induce Biologics USA, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05972616 being conducted?
This trial has 1 study location across Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Degenerative Disc Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05972616's enrollment target sits among peer trials
53 29th of 42 higher than 14 of 42 other Degenerative Disc Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Degenerative Disc Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
OssDsign® Spine Registry Study ("Propel")
RECRUITING
-
A Study to Evaluate the Effectiveness of IDCT (Intradiscal Cell Therapy) in Subjects With One Level, Symptomatic Mild to Moderate Lumbar Degenerative Disc Disease
RECRUITING · Phase 3
-
LDGraft in Single Level Anterior Lumbar Interbody Fusion (ALIF)
RECRUITING · Phase 1
-
Investigation of DEXA-C Anterior Cervical Interbody System
RECRUITING · NA
-
Post Marketing Study of MagnetOs Easypack Putty Standalone Compared to Demineralized Bone Matrix or Fibers Mixed With Autograft in Patients Undergoing Posterolateral Lumbar Fusion
RECRUITING · NA
-
Trial for Treating Painful Degenerative Disc Disease
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04177004 · 53 participants · Phase 1
Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant
- NCT04199741 · 53 participants · Phase 1
PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56
- NCT04835129 · 53 participants · Phase 2
Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
- NCT04913805 · 53 participants · Phase 2
Matching Perfusion and Metabolic Activity in HFpEF
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI